Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 4/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | CASR | P41180 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351018 | 1.00 | AURKA (0.31) | AURKARPS6KB1IDO1BACE1MAPT | |
| SCHEMBL2348859 | 1.00 | AURKA (0.31) | AURKARPS6KB1IDO1BACE1MAPT | |
| SCHEMBL2349108 | 0.83 | BACE1 (0.43) | AURKARPS6KB1BACE1 | |
| SCHEMBL2352689 | 0.83 | BACE1 (0.43) | AURKARPS6KB1BACE1 | |
| SCHEMBL2353624 | 0.82 | BACE1 (0.34) | AURKARPS6KB1IDO1BACE1MAPT | |
| SCHEMBL2353305 | 0.79 | IDO1 (0.36) | AURKARPS6KB1IDO1BACE1RXFP1 | |
| SCHEMBL2353309 | 0.79 | IDO1 (0.36) | AURKARPS6KB1IDO1BACE1RXFP1 | |
| SCHEMBL2352506 | 0.78 | BACE1 (0.43) | BACE1 | |
| SCHEMBL2349221 | 0.76 | BACE1 (0.34) | AURKARPS6KB1IDO1BACE1MAPT | |
| SCHEMBL2352538 | 0.75 | HTT (0.36) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | BUCKMAN BRAD (US) | 2011-12-29 | — | — | US | disclosed |
| US-8008325-B2 | Plasma carboxypeptidase B inhibitors | BAYER SCHERING PHARMA AG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-2204373-A1 | Phosphonic acid as Plasma Carboxypeptidase B Inhibitors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-07-07 | — | — | EP | disclosed |
| US-7528173-B2 | Plasma carboxypeptidase B inhibitors | SCHERING AKTIENGESELLSHAFT (DE) | 2009-05-05 | — | — | US | disclosed |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | BUCKMAN BRAD | 2009-04-09 | — | — | US | disclosed |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319366-A1 | Plasma Carboxypeptidase B Inhibitors | CPB1, CPB2, CPA1 | AURKA 3548/4885RPS6KB1 1196/4885IDO1 1366/4885 |
| US-20090093520-A1 | PLASMA CARBOXYPEPTIDASE B INHIBITORS | CPB1, CPB2, CPA1 | AURKA 3548/4885RPS6KB1 1196/4885IDO1 1366/4885 |
| US-20060247213-A1 | Plasma carboxypeptidase b inhibitors | CPB1, CPB2, CPA1 | AURKA 3612/4885RPS6KB1 1156/4885IDO1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.